Six monthly antimicrobial utilisation reports


In addition to the six monthly reports below, National Utilisation Surveillance Program (NAUSP) also produces detailed annual reports showing usage of an expanded number of antimicrobials both nationally and in individual Australian public and private hospitals in a de-identified manner.

NAUSP definitions updated January 2021

Prior to January 2021, total-hospital acute usage rates included usage in the emergency department and operating theatres. Usage in these areas will now be reported separately relative to patient presentations (replacing occupied bed days as a measure of patient activity), and are not included in total-hospital (or non-Critical Care) from January 2021.

COVID-19

Some usage rates continued to fluctuate during the January to June 2021 reporting period. OBDs dropped markedly for some hospitals in some months, with consequential increases in reported usage rates. Usage rates should be interpreted with caution as they reflect the quantity of antimicrobials distributed or dispensed from pharmacy and not actual consumption at patient level. Some hospitals were unable to submit complete data for the reporting period due to the impact of COVID-19 on staffing capacity.

National aggregated reports by peer group

January 2020 to December 2021

These 2-year longitudinal reports include aggregated usage by all contributors for both total hospital use and Critical Care (including Intensive Care and High Dependency Units) use.  

All contributing hospitals (PDF 947KB)

Benchmarking reports by state/territory (total-hospital)

July 2021 to December 2021

These six-monthly reports allow contributors to compare their usage with other hospitals within their state or territory.

New South Wales and Australian Capital Territory with hospital data de-identified (PDF 91KB)

Queensland and Northern Territory with hospital data de-identified (PDF 88KB)

South Australia with hospital data de-identified (PDF 85KB)

Victoria with hospital data de-identified (PDF 89KB)

Western Australia with hospital data de-identified (PDF 87KB)

Tasmania with hospital data de-identified (PDF 86KB)

Benchmarking reports by state/territory (Emergency Department)

July 2021 to December 2021

For hospitals able to submit Emergency Department (ED) usage data, these reports allow contributors to benchmark their ED usage rates with other hospitals in their state/territory.

New South Wales and Australian Capital
Territory

Queensland and Northern Territory

South Australia

Victoria

Western Australia

Tasmania

Benchmarking reports by peer group (Critical Care Unit)

For hospitals able to submit usage data for their Critical Care Unit, these reports allow contributors to benchmark their Critical Care usage rates (Intensive Care and/or High Dependency Units) with other hospitals in their AIHW peer group.

Principal Referral

Acute Group A

Acute Group B

Acute Group C

Antifungal benchmarking reports by state/territory

These six-monthly reports allow contributors to compare their antifungal usage rates with other hospitals within their state or territory. Usage rates of antifungals are highly dependent on the casemix (e.g. haematology/oncology or transplant services) and acuity of the hospital.

New South Wales and Australian Capital Territory (PDF 634KB)

Queensland and Northern Territory (PDF 638KB)

South Australia (PDF 644KB)

Victoria (PDF 165KB)

Western Australia (PDF 649KB)

Tasmania (PDF 883)

Contributor reports from the NAUSP portal

Hospitals contributing to NAUSP can download reports directly from the NAUSP portal showing longitudinal usage rates for their individual hospitals. These contain charts comparing the individual hospital’s usage compared to the average usage at similarly peered hospitals. Hospitals that contribute usage data for particular specialties/locations can access usage reports for critical care, haematology/oncology, respiratory and obstetrics/gynaecology. 

Disclaimer

Usage rates reported in previously published NAUSP reports may differ from current reports. The Defined Daily Dose (DDD) values for some commonly used antimicrobials were changed by the WHO in January 2019. Due to these changes, usage rates in more recently published reports may not be directly comparable with prior reports that utilised the former DDD values for the analysis. In addition to amendments to WHO DDDs, rates may differ as a result of retrospective data adjustments or varying numbers of hospitals contributing to aggregated data.

Acknowledgement

The Australian Department of Health provides funding for the administration of NAUSP and the analyses of NAUSP data and related reports for the AURA Surveillance System.

Citation

Unless otherwise stated within a report, please attribute the reports found on this webpage (and any material sourced from them) using the following citation:

National Antimicrobial Utilisation Surveillance Program. [insert report title]. Adelaide: SA Health; [insert year of publication].

Further reading

Further information

For further information on National Antimicrobial Utilisation Surveillance Program, contact the Program Coordinator.